ACR Convergence 2023

November 10-15, 2023. San Diego, CA.

View by Number View by Title View Sessions

Abstract Number: 1839

Value of Small Fiber Neuropathy in Fibromyalgia Patients in a Rheumatological Setting
Abstract Number: 1840

Value of Various Intra-Articular Injections for Knee Osteoarthritis Management
Abstract Number: 1841

Clinical Trial Perceptions Among Male Patients with Systemic Lupus Erythematosus (SLE): Georgians Organized Against Lupus (GOAL) Cohort
Abstract Number: 1842

Reduction in the Concomitant Ordering of Erythrocyte Sedimentation Rate and C-Reactive Protein Within the Rheumatology Clinics at an Academic Medical Center
Abstract Number: 1843

Detection of Clinically Relevant Subgroups in Patients Undergoing Knee Replacement Using Machine Learning
Abstract Number: 1844

Are Patients with Inflammatory Rheumatic Diseases Ready for Studies with Medical Cannabis? – Results from a Digital Survey
Abstract Number: 1845

Development of a Scoring System for Accurate Lupus Nephritis Case Identification in Real-World Databases
Abstract Number: 1846

A Longitudinal Study: The Benefits of Non-Pharmacological Approaches to Improve Self-Reported Pain, Stiffness, and Fatigue in Individuals with Musculoskeletal Disorders
Abstract Number: 1847

Influence of Seasonal Changes on Adherence in Rheumatoid Arthritis Patients
Abstract Number: 1848

Demographic and Clinical Factors Associated with HPV Vaccination in Young Adults with Rheumatic Disease
Abstract Number: 1849

Impact of the First Three Waves of the Covid-19 Pandemic on Everyday Restrictions and Clinical Care of Patients with Spondyloarthritis Across Europe – Results from the EuroSpA Collaboration
Abstract Number: 1850

Long-term Glucocorticoid Use in a Cohort of Elderly Early Rheumatoid Arthritis Patients: A Joint Analysis of Medicare and the Rheumatology Informatics System for Effectiveness (RISE) Data
Abstract Number: 1851

Healthcare Providers’ Experiences of a Mandatory Nationwide Transition to an Adalimumab Biosimilar
Abstract Number: 1852

Human Papillomavirus Vaccine Uptakes in Ethnically Diverse Women Living with Systemic Lupus Erythematosus
Abstract Number: 1853

Each Joint in a 28 Joint Count Is More Likely to Be Affected by Deformity/Limited Motion Than by Swelling in Rheumatoid Arthritis Patients with Long Disease Duration: Deformity/Limited Motion Should Be Included in Joint Counts Performed in Routine Care

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].